Metastatic Urinary Bladder Carcinoma on Palliative Chemotherapy Showing Rapid Progression on Interim Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
- PMID: 35478686
- PMCID: PMC9037868
- DOI: 10.4103/ijnm.ijnm_51_21
Metastatic Urinary Bladder Carcinoma on Palliative Chemotherapy Showing Rapid Progression on Interim Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
Abstract
Bladder cancer (BC) is among the top ten most common cancer types globally. Muscle invasive BC has a high incidence of metastasis. Metastatic BC has a poor prognosis and limited treatment options. Here, we present a middle-aged man with oligometastatic BC, which was treated with palliative chemotherapy. He had significant clinical improvement. However, interim 18F-Fluorodeoxyglucose positron emission tomography/computed tomography demonstrates a rapid disease progression extensive metastasis.
Keywords: Fluorodeoxyglucose positron emission tomography/computed tomography; metastatic disease; progressive disease; treatment response evaluation; urinary bladder carcinoma.
Copyright: © 2022 Indian Journal of Nuclear Medicine.
Conflict of interest statement
There are no conflicts of interest.
Figures


Similar articles
-
Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.Oncologist. 2017 May;22(5):526-534. doi: 10.1634/theoncologist.2016-0334. Epub 2017 Apr 4. Oncologist. 2017. PMID: 28377466 Free PMC article.
-
Prognostic significance of interim 18 F-fluorodeoxyglucose positron emission tomography-computed tomography volumetric parameters in metastatic or recurrent gastric cancer.Asia Pac J Clin Oncol. 2018 Oct;14(5):e302-e309. doi: 10.1111/ajco.12833. Epub 2017 Dec 10. Asia Pac J Clin Oncol. 2018. PMID: 29226597
-
[18F]Fluorodeoxyglucose-positron emission tomography/computed tomography response evaluation can predict histological response at surgery after induction chemotherapy for oligometastatic bladder cancer.Scand J Urol. 2017 Aug;51(4):308-313. doi: 10.1080/21681805.2017.1321579. Epub 2017 May 22. Scand J Urol. 2017. PMID: 28532260
-
Positron emission tomography for prostate, bladder, and renal cancer.Semin Nucl Med. 2004 Oct;34(4):274-92. doi: 10.1053/j.semnuclmed.2004.06.004. Semin Nucl Med. 2004. PMID: 15493005 Review.
-
18F-fluorodeoxyglucose positron emission tomography/computed tomography in the evaluation of clinically node-negative non-small cell lung cancer.Thorac Cancer. 2019 Mar;10(3):413-420. doi: 10.1111/1759-7714.12978. Epub 2019 Jan 21. Thorac Cancer. 2019. PMID: 30666803 Free PMC article. Review.
References
-
- Višnjar T, Romih R, Zupančič D. Lectins as possible tools for improved urinary bladder cancer management. Glycobiology. 2019;29:355–65. - PubMed
-
- Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol. 2017;71:96–108. - PubMed
-
- Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63:234–41. - PubMed
-
- Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD. Metastatic pattern of bladder cancer: Correlation with the characteristics of the primary tumor. AJR Am J Roentgenol. 2011;196:117–22. - PubMed
-
- Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10–21. - PubMed
LinkOut - more resources
Full Text Sources